KR102708620B1 - Composition for preventing hair loss and promoting hair growth - Google Patents
Composition for preventing hair loss and promoting hair growth Download PDFInfo
- Publication number
- KR102708620B1 KR102708620B1 KR1020200113897A KR20200113897A KR102708620B1 KR 102708620 B1 KR102708620 B1 KR 102708620B1 KR 1020200113897 A KR1020200113897 A KR 1020200113897A KR 20200113897 A KR20200113897 A KR 20200113897A KR 102708620 B1 KR102708620 B1 KR 102708620B1
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- composition
- growth
- promoting
- cordycepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 230000003779 hair growth Effects 0.000 title claims abstract description 59
- 230000001737 promoting effect Effects 0.000 title claims abstract description 40
- 230000003658 preventing hair loss Effects 0.000 title claims abstract description 37
- 210000004209 hair Anatomy 0.000 claims abstract description 74
- 230000000694 effects Effects 0.000 claims abstract description 42
- 102000015735 Beta-catenin Human genes 0.000 claims abstract description 14
- 108060000903 Beta-catenin Proteins 0.000 claims abstract description 14
- 230000019491 signal transduction Effects 0.000 claims abstract description 4
- 230000035755 proliferation Effects 0.000 claims abstract 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims description 63
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims description 63
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims description 63
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 60
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 60
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 60
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 30
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 30
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 30
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 30
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 30
- 235000004866 D-panthenol Nutrition 0.000 claims description 30
- 239000011703 D-panthenol Substances 0.000 claims description 30
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 30
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 30
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 claims description 30
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 claims description 30
- 239000004228 Riboflavin-5'-Phosphate Substances 0.000 claims description 30
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 claims description 30
- 229960005305 adenosine Drugs 0.000 claims description 30
- 229960000458 allantoin Drugs 0.000 claims description 30
- 229940059958 centella asiatica extract Drugs 0.000 claims description 30
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 30
- 229940074393 chlorogenic acid Drugs 0.000 claims description 30
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 30
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 30
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 30
- 229960003949 dexpanthenol Drugs 0.000 claims description 30
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 claims description 30
- 239000011768 flavin mononucleotide Substances 0.000 claims description 30
- 229960003966 nicotinamide Drugs 0.000 claims description 30
- 235000005152 nicotinamide Nutrition 0.000 claims description 30
- 239000011570 nicotinamide Substances 0.000 claims description 30
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 30
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 claims description 30
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 claims description 30
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 claims description 30
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 claims description 30
- 229960004889 salicylic acid Drugs 0.000 claims description 30
- -1 Rhein Chemical compound 0.000 claims description 29
- 229940011399 escin Drugs 0.000 claims description 26
- 229930186222 escin Natural products 0.000 claims description 26
- 210000004761 scalp Anatomy 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 235000015961 tonic Nutrition 0.000 claims description 10
- 230000001256 tonic effect Effects 0.000 claims description 10
- 235000013376 functional food Nutrition 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 229960000716 tonics Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 2
- 239000000118 hair dye Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 abstract description 23
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 description 38
- 230000003676 hair loss Effects 0.000 description 27
- 208000024963 hair loss Diseases 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 108050003627 Wnt Proteins 0.000 description 14
- 102000013814 Wnt Human genes 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 230000003698 anagen phase Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 210000003780 hair follicle Anatomy 0.000 description 12
- 238000011282 treatment Methods 0.000 description 10
- 230000003778 catagen phase Effects 0.000 description 9
- 230000016507 interphase Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 206010068168 androgenetic alopecia Diseases 0.000 description 7
- 229960003632 minoxidil Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000031774 hair cycle Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 2
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000003797 telogen phase Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HHCLNZBCCQDVOQ-UHFFFAOYSA-N 1-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]pyrazol-3-yl]methyl]piperazin-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(N1CC2=C(CC1)NN=N2)=O)CN1C(CNCC1)=O HHCLNZBCCQDVOQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZYPDJSJJXZWZJJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-piperidin-4-yloxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCNCC1 ZYPDJSJJXZWZJJ-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 101100011509 Drosophila melanogaster Baldspot gene Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000044880 Wnt3A Human genes 0.000 description 1
- 108700013515 Wnt3A Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000003662 hair growth rate Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000002488 outer root sheath cell Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- OWGHQYPQNSZTFQ-UHFFFAOYSA-M triethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](CC)(CC)CC OWGHQYPQNSZTFQ-UHFFFAOYSA-M 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 탈모방지 및 모발성장 촉진용 조성물에 관한 것이다. 본 발명의 탈모방지 및 모발성장 촉진용 조성물은 모유두 세포의 증식을 촉진하고, Wnt/베타-카테닌 신호전달계를 활성화시켜, 탈모방지 및 모발성장 촉진 효과가 현저하게 우수하다. 또한, 본 발명의 탈모방지 및 모발성장 촉진용 조성물은 특정한 2 이상의 유효성분의 조합을 통해 탈모방지 및 모발성장 촉진에 현저한 상승 효과를 나타낼 수 있다.The present invention relates to a composition for preventing hair loss and promoting hair growth. The composition for preventing hair loss and promoting hair growth of the present invention promotes the proliferation of hair papilla cells and activates the Wnt/beta-catenin signaling pathway, thereby exhibiting remarkably excellent effects in preventing hair loss and promoting hair growth. In addition, the composition for preventing hair loss and promoting hair growth of the present invention can exhibit a remarkable synergistic effect in preventing hair loss and promoting hair growth through a combination of two or more specific effective ingredients.
Description
본 발명은 탈모방지 및 모발성장 촉진용 조성물에 관한 것이다.The present invention relates to a composition for preventing hair loss and promoting hair growth.
시대가 변하면서 미용에 대한 관심이 날로 높아가는 과정에 모발은 중요한 한 부분을 차지하고 있다. 모발은 피부 표면에서 생산된 가늘고 각질화된 구조다. 이것은 외부 충격에 대한 쿠션 역할과 더불어 직사광선, 한랭, 마찰, 위험 등 외부 자극으로부터 인체를 보호하고 신체에 유해한 비소, 수은, 아연 등의 중금속이 체외로 배출되는 기능을 하며 현대에 와서는 장식의 미용 측면도 강조되고 있다. 그러나 식생활 변화나 내외적 스트레스 증가를 비롯하여 여러 원인에 의해 탈모를 호소하는 사람들이 늘어나고 있다. 탈모는 유전적 요인이 가장 주요한 원인으로 작용한다고 알려져 있지만 앞서 말한 바와 같이 사회적 스트레스의 증가, 환경오염, 잦은 파마와 염색, 및 잘못된 두피 관리들도 탈모의 원인으로 대두되고 있다.As times change and interest in beauty increases, hair is playing an important role. Hair is a fine, keratinized structure produced on the surface of the skin. In addition to acting as a cushion against external impact, it protects the human body from external stimuli such as direct sunlight, cold, friction, and danger, and functions to excrete heavy metals such as arsenic, mercury, and zinc that are harmful to the body. In modern times, the aesthetic aspect of decoration is also emphasized. However, the number of people complaining of hair loss due to various reasons, including changes in diet and increased internal and external stress, is increasing. It is known that genetic factors are the main cause of hair loss, but as mentioned above, increased social stress, environmental pollution, frequent perms and dyeing, and improper scalp management are also emerging as causes of hair loss.
사람의 모발은 약 10만-15만 개 정도이며, 각각의 모발은 서로 다른 성장 주기를 가진다. 발생 초기 모낭(hair follicle)의 형성은 베타-카테닌(β-catenin)의 작용에 의해 기저층 표피 세포에 의해 플라코드(placode)가 형성된다(Sarah E. Miller, 2002). 형성된 플라코드로부터 신호를 받은 진피 섬유아세포가 피부 응축체(dermal condensate)를 형성한다. 동시에 플라코드는 진피 방향으로 성장, 함입하여 피부 응축체와 합쳐 일차 모발 배종(primary hair germ)을 형성한다. 모발 배종을 형성한 표피 세포는 발생하는 진피 방향으로 길게 성장하고, 다층으로 이루어진 긴 기둥형태의 구조물인 헤어 페그(hair peg)를 형성하는 동시에 피부 응축체는 구형의 모유두(dermal papilla)로 형성된다. 헤어 페그의 끝쪽은 점점 두꺼워져 모구(hair bulb)가 형성되는데 모구는 모유두를 감싼 형태가 되어 모낭이 완성되고 모낭 내부의 표피 세포가 분화하여 모발이 생성된다. A human has about 100,000-150,000 hairs, and each hair has a different growth cycle. In the early stage of development, a hair follicle is formed by basal epidermal cells forming a placode through the action of β-catenin (Sarah E. Miller, 2002). Dermal fibroblasts that receive signals from the formed placode form a dermal condensate. At the same time, the placode grows and invaginates toward the dermis, merging with the dermal condensate to form a primary hair germ. The epidermal cells that form the hair germ grow long in the direction of the developing dermis and form a hair peg, a long, columnar structure made of multiple layers, and at the same time, the dermal condensate is formed into a spherical dermal papilla. The tip of the hair peg gradually thickens to form a hair bulb. The hair bulb surrounds the hair papilla to complete the hair follicle, and the epidermal cells inside the hair follicle differentiate to produce hair.
처음 생성된 모발은 성장기 시기를 거쳐 퇴화기, 휴지기로 들어가며, 이후 모발이 탈락된 후 다시 성장기로 들어가는 주기를 돈다. 모발 성장 주기는 3단계로 구성되는데, 모발이 가장 활발하게 성장하는 성장기(anagen stage), 모발의 퇴화가 시작되는 퇴화기(catagen stage), 및 모발의 성장이 멈추거나 휴식에 접어드는 휴지기(telogen stage)로 분류된다.The first hair that is created goes through a growth phase, a degenerative phase, a resting phase, and then falls out and enters the growth phase again. The hair growth cycle is divided into three stages: the growth phase (anagen stage) in which hair grows most actively, the degenerative phase (catagen stage) in which hair begins to deteriorate, and the resting phase (telogen stage) in which hair stops growing or enters a resting state.
이러한 모발의 성장 주기를 조절하는데 있어서, 모낭을 구성하는 모유두 세포 및 모낭 줄기세포를 포함한 외모근초 세포(outer root sheath cell)의 활성, 및 이들 세포에서 생산되는 다양한 사이토카인 및 성장 인자가 중요한 역할을 한다고 알려져 있다. 예를 들어 DKK-1(Dickkopf-1)은 모낭 성장 저해와 사멸에 중요한 역할을 한다(J Invest. Dermatol,2008:128(2)). 한편, 주기적인 모발 성장을 위해서는 모낭의 재생과 줄기세포의 활성화가 이루어져야 하며, 이는 Wnt/β-카테닌의 생성 및 활성화에 의해 이루어지는 것으로 알려져 있다(Nature 2007:447(7142)).In regulating the hair growth cycle, it is known that the activity of outer root sheath cells, including hair papilla cells and hair follicle stem cells that constitute the hair follicle, and various cytokines and growth factors produced by these cells play an important role. For example, DKK-1 (Dickkopf-1) plays an important role in hair follicle growth inhibition and death (J Invest. Dermatol, 2008:128(2)). Meanwhile, for cyclical hair growth, regeneration of hair follicles and activation of stem cells must occur, and it is known that this is achieved by the production and activation of Wnt/β-catenin (Nature 2007:447(7142)).
이외에도 VEGF, IGF-1, 또는 FGF 등의 성장인자는 모발의 성장기를 촉진시키는 것으로 알려져 있고, TGFb-1, EGF 등은 모낭의 퇴행기를 유도하는 성장 인자로 알려져 있다. In addition, growth factors such as VEGF, IGF-1, or FGF are known to promote the growth phase of hair, and TGFb-1, EGF, etc. are known to be growth factors that induce the regression phase of hair follicles.
일반적으로 탈모증이라 함은 이러한 주기 중에서 성장기의 모발 비율이 짧아지고 퇴행기 또는 휴지기의 모발이 많아져 비정상적으로 모발이 탈락하는 숫자가 많아지는 것을 일컫는다. 탈모는 정상적인 현상이나 정상인 사람이 성장기 상태의 모발이 많은 데 비해, 보통 탈모증(Alopecia)인 사람은 휴지기 상태의 모발이 많아 눈으로 보이는 탈모 현상이 나타내게 된다. 탈모증을 나타내는 사람들의 특징은 모발의 소형화에 있다. 탈모가 진행될수록 성장기의 기간이 짧아지고 퇴행기, 휴지기로의 이행이 촉진되며 뒤이은 모유두의 부피가 작아져 모낭은 점점 소형화된다. 따라서 탈모의 치료를 위해서는 휴지기 상태의 모낭을 성장기로 빨리 갈 수 있도록 하고, 짧아진 성장기를 늘려주는 것이 중요하다.Alopecia generally refers to a condition in which the proportion of hair in the growth phase becomes shorter and the proportion of hair in the catagen or resting phase increases, resulting in an abnormal increase in the number of hairs that fall out. Hair loss is a normal phenomenon, but while normal people have more hair in the growth phase, people with alopecia usually have more hair in the resting phase, resulting in visible hair loss. A characteristic of people with alopecia is the miniaturization of hair. As hair loss progresses, the period of the growth phase shortens, the transition to the catagen and resting phases is accelerated, and the volume of the subsequent hair papilla decreases, causing the hair follicles to become smaller. Therefore, in order to treat hair loss, it is important to enable hair follicles in the resting phase to quickly transition to the growth phase and to lengthen the shortened growth phase.
그 외에 가장 많은 탈모 환자가 속하고 있는 탈모증인 남성형 탈모증은 '안드로겐성 탈모증'으로도 불린다. 남성형 탈모증이 평균적으로 젊은 20∼30대의 남성에게서 많이 나타난다. 이는 안드로겐성 탈모증이 유전적 영향뿐만 아니라 남성 호르몬의 작용 및 나이에 의하여 좌우되기 때문이다. 남성형 탈모증의 탈모 발생 주요원인으로 남성호르몬인 테스토스테론으로 연구되고 있으며, 탈모반의 형태와 진행 상태에 따라 다양하게 구분된다. 테스토스테론으로 인한 남성형 탈모증은 남성호르몬과 활성 효소인 5α-리덕타아제의 결합으로 발생된 디하이드로테스토스테론(DHT: Dihydro-testosterone)이 모낭에 작용하여 세포 분열을 억제시키고 모발의 성장을 저해하는 데에서 발생된다.In addition, male pattern baldness, which is the most common type of hair loss, is also called 'androgenetic alopecia'. Male pattern baldness occurs most often in young men in their 20s and 30s on average. This is because androgenetic alopecia is affected not only by genetic influences but also by the action of male hormones and age. The main cause of hair loss in male pattern baldness is being studied as the male hormone testosterone, and it is classified in various ways depending on the type and progression of the bald spot. Male pattern baldness caused by testosterone occurs when dihydrotestosterone (DHT), which is generated by the combination of male hormone and the active enzyme 5α-reductase, acts on the hair follicle to inhibit cell division and hair growth.
활성 효소인 5α-리덕타아제가 두피 상에 분포하는 양상에 따라 탈모의 형태가 다르게 나타난다. 활성 효소가 많이 분포하는 정수리 부위는 DHT의 영향으로 세포 분열이 둔화되고 모발의 모주기가 짧아져 모발의 연모화와 탈모 현상이 나타나지만, 측두부나 후두부의 경우에는 상대적으로 활성 효소의 활성도가 약하고 또한 여성호르몬의 영향을 받아 탈모가 쉽게 나타나지 않는다. 현재 남성형 탈모의 관리법으로 모발 이식술 또는 약물 요법 등이 활용되고 있다.Hair loss patterns vary depending on the distribution pattern of the active enzyme, 5α-reductase, on the scalp. The crown area, where the active enzyme is distributed in large quantities, has slow cell division and a shortened hair cycle due to the influence of DHT, resulting in hair softening and hair loss. However, in the temporal region or the back of the head, the activity of the active enzyme is relatively low, and hair loss does not occur easily due to the influence of female hormones. Currently, hair transplantation or drug therapy is used as a management method for male pattern baldness.
앞서 언급했듯이 탈모의 원인으로 남성호르몬 작용, 피지 분비 과다, 혈액순환 불량, 과산화물이나 세균 등에 의한 두피 기능 저하, 유전적 요인, 노화, 또는 스트레스 등이 논의되어 왔다. 그러나 현재까지 탈모에 관한 명확한 원인은 밝혀져 있지 않은 상태이며, 매우 복잡한 작용이 얽혀 있는 것으로 알려져 있다.As mentioned earlier, the causes of hair loss have been discussed, including male hormones, excessive sebum secretion, poor blood circulation, decreased scalp function due to peroxides or bacteria, genetic factors, aging, or stress. However, the exact cause of hair loss has not yet been identified, and it is known to be a very complex intertwined process.
이처럼 다양하고 복잡한 탈모 원인에 대하여, 현재까지 알려진 탈모 방지 제품에는 유효성분으로 혈행 촉진, 모근 기능 강화, 두피 보습 효과, 비듬 방지 효과, 항산화 효과, 모발성장기 연장 효과, 또는 남성호르몬 작용 억제 등을 목적으로 하는 성분 등이 포함되어 있으나, 효과 면에서 뚜렷한 효과를 지닌 것은 아직까지 없는 상태이고 부작용의 문제가 제기되기도 한다.For such diverse and complex causes of hair loss, currently known hair loss prevention products contain ingredients that aim to promote blood circulation, strengthen hair root function, moisturize the scalp, prevent dandruff, have antioxidant effects, extend the hair growth period, or suppress androgen action. However, none of them have a clear effect and there are also concerns about side effects.
현재 미국식품의약품안전청(FDA)에서 승인을 받은 도포제의 탈모 치료제는 미녹시딜(2,4-diamino-6-piperidinopyrimidine-3-oxide)이 유일하지만, 32주에서 48주 사용 시 그 효과가 각각 38% 및 13%로 만족스럽지 못한 실정이며(J Am Acad Dermatol. 2002. 47(3)), 앞머리에는 효과가 떨어진다는 단점이 있다.Currently, the only topical hair loss treatment approved by the U.S. Food and Drug Administration (FDA) is minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxide), but its effectiveness is unsatisfactory at 38% and 13% after 32 and 48 weeks of use, respectively (J Am Acad Dermatol. 2002. 47(3)), and it has the disadvantage of being less effective on the frontal hairline.
본 발명이 해결하고자 하는 과제는 인체에 안전하고 부작용이 없으면서도 우수한 모발 성장 촉진 효과 및/또는 탈모 방지 효과를 갖는 탈모 방지 또는 모발 성장 촉진용 조성물을 제공하는 것이다.The problem to be solved by the present invention is to provide a composition for preventing hair loss or promoting hair growth that is safe for the human body and has no side effects, while having an excellent hair growth promoting effect and/or hair loss prevention effect.
또한, 본 발명이 해결하고자 하는 과제는 상기 탈모 방지 또는 모발 성장 촉진용 조성물을 포함하는 헤어 또는 두피용 제품을 제공하는 것이다.In addition, the problem to be solved by the present invention is to provide a hair or scalp product comprising the composition for preventing hair loss or promoting hair growth.
본 발명자들은 종래의 탈모 치료제에서 부작용이 발생하거나 또는 효과가 미약하다는 등의 단점 없이, 인체에 안전하면서도 탈모 방지 또는 모발 성장에 효과적으로 작용할 수 있는 조성물을 개발하고자 예의 노력하였다.The present inventors have made great efforts to develop a composition that is safe for the human body and can effectively prevent hair loss or promote hair growth, without the disadvantages of conventional hair loss treatments, such as side effects or poor effectiveness.
그 결과, 본 발명자들은 코르디세핀(Cordycepin)이 탈모를 방지하고 모발 성장을 촉진하는 효과가 있음을 발견하였다. 나아가, 본 발명자들은 상기 코르디세핀에 에스신(Escin), 아데노신(Adenosine), 알란토인(Allantoin), 병풀(Centella asiatica) 추출물, 덱스판테놀(Dexpanthenol), 나이아신아마이드(Niacinamide), 살리실산(Salicylic acid), 퀘르시트린(Quercitrin), 클로로젠산(Chlorogenic acid), 레인(Rhein), 및 리보플라빈 5'-포스페이트(Riboflavin 5’-phosphate)로 이루어진 군으로부터 선택된 1종 이상을 조합하는 경우, 놀랍게도 탈모 방지 및 모발 성장 촉진에 현저한 상승 효과가 나타남을 발견하여 본 발명을 완성하게 되었다.As a result, the inventors of the present invention found that cordycepin has the effect of preventing hair loss and promoting hair growth. Furthermore, the inventors of the present invention surprisingly found that when cordycepin is combined with at least one selected from the group consisting of escin, adenosine, allantoin, Centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate, a remarkable synergistic effect in preventing hair loss and promoting hair growth is exhibited, thereby completing the present invention.
본 발명은 코르디세핀을 유효성분으로 포함하는 탈모 방지 또는 모발 성장 촉진용 조성물을 제공한다. 또한, 본 발명은, 상기 조성물에 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 유효성분으로 추가적으로 포함하는 탈모 방지 또는 모발 성장 촉진용 조성물을 제공한다. 또한, 본 발명의 조성물은 상기 유효성분들의 약학적으로 또는 화장품학적으로 허용 가능한 염을 포함할 수 있다.The present invention provides a composition for preventing hair loss or promoting hair growth, which comprises cordycepin as an effective ingredient. In addition, the present invention provides a composition for preventing hair loss or promoting hair growth, which additionally comprises at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate as an effective ingredient. In addition, the composition of the present invention may comprise a pharmaceutically or cosmetically acceptable salt of the above-described effective ingredients.
구체적으로, 본 발명의 발명자들은 상기 각각의 성분들이 모유두 세포의 활성을 촉진시키고 Wnt/베타-카테닌 신호전달계의 활성을 증진시켜, 모발의 생리주기를 퇴행기 내지 휴지기에서 성장기(활성기)로 가는데 중요한 역할을 담당하는 것을 인비트로(in-vitro) 실험을 통해 확인하였다. 본 발명의 탈모 방지 또는 모발 성장 촉진용 조성물은 상기 효과를 통해 모발의 성장 주기 중 휴지기에서 성장기로 이행되는 주기를 단축시킴으로써 모발의 성장을 촉진시키고 퇴행기로의 전환을 늦추어 탈모를 방지하고 모발 성장을 촉진하는 것으로 예상된다. 그러나 본 발명은 이러한 기전에 한정되는 것은 아니다.Specifically, the inventors of the present invention confirmed through in vitro experiments that each of the above components promotes the activity of hair papilla cells and enhances the activity of the Wnt/beta-catenin signaling pathway, thereby playing an important role in transitioning the hair menstrual cycle from the catagen or resting phase to the growth phase ( active phase). It is expected that the composition for preventing hair loss or promoting hair growth of the present invention promotes hair growth and delays the transition to the catagen phase by shortening the cycle from the resting phase to the growing phase in the hair growth cycle through the above effects, thereby preventing hair loss and promoting hair growth. However, the present invention is not limited to this mechanism.
또한, 본 발명의 발명자들은 체외 조직 배양 실험을 통해 모발 성장 효과를 확인하였으며, 본 발명의 조성물을 탈모증 환자에게 처리할 때 단위면적당 모발 개수 및 모발 두께가 개선되는 효과가 현저하게 우수함을 확인하였다. 추가적으로, 시판되고 있는 제품인 미녹시딜과 효과를 비교 실험한 결과, 본 발명의 조성물은 탈모 방지 또는 발모 촉진 효과가 미녹시딜에 비해 현저하게 우수함을 확인하였다.In addition, the inventors of the present invention confirmed the hair growth effect through an in vitro tissue culture experiment, and confirmed that when the composition of the present invention is treated on alopecia patients, the effect of improving the number of hairs per unit area and hair thickness is significantly excellent. Additionally, as a result of a comparative experiment with the effect of minoxidil, a commercially available product, it was confirmed that the composition of the present invention is significantly superior to minoxidil in the effect of preventing hair loss or promoting hair growth.
일 실시예에서, 상기 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상은 조성물 총 중량 대비 0.00001 내지 50 중량%, 바람직하게 0.0001 내지 20 중량%, 더욱 바람직하게 0.001 내지 10 중량%, 더욱 더 바람직하게 0.01 내지 5 중량%로 포함될 수 있다. 각 성분의 함량이 0.00001 중량% 미만일 경우에는 모발의 성장을 유도하는 효과가 미약하고, 50 중량% 초과일 경우에는 제형의 안정성이 떨어질 수 있다.In one embodiment, the cordycepin; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate may be included in an amount of 0.00001 to 50 wt%, preferably 0.0001 to 20 wt%, more preferably 0.001 to 10 wt%, and even more preferably 0.01 to 5 wt% based on the total weight of the composition. When the content of each component is less than 0.00001 wt%, the effect of inducing hair growth is weak, and when it exceeds 50 wt%, the stability of the formulation may deteriorate.
또한, 본 발명은 상기 탈모 방지 또는 모발 성장 촉진용 조성물을 포함하는 의약 조성물, 의약외품용 조성물, 화장료 조성물 또는 건강기능식품 조성물을 제공한다. 본 발명의 조성물은 통상적으로 피부에 적용시킬 수 있는 어떠한 형태로도 제형화될 수 있으나, 바람직하게 피부 외용제의 형태로 제형화될 수 있다. 본 발명의 조성물은 예를 들어 액상, 크림상, 페이스트상, 또는 고체상 등 피부에 적용시킬 수 있는 제형으로 제조될 수 있다.In addition, the present invention provides a pharmaceutical composition, a composition for quasi-drugs, a cosmetic composition, or a health functional food composition comprising the composition for preventing hair loss or promoting hair growth. The composition of the present invention may be formulated in any form that can be applied to the skin, but is preferably formulated in the form of a skin external preparation. The composition of the present invention may be prepared in a formulation that can be applied to the skin, such as a liquid, cream, paste, or solid form.
본 발명의 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상은 상기 조성물 또는 제형에 탈모 방지제 또는 모발 성장 촉진제로 포함될 수 있다.The cordycepin of the present invention; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate may be included in the composition or formulation as an anti-hair loss agent or a hair growth promoter.
일 실시예에서, 본 발명의 제형이 액상인 경우에는 담체 성분으로 용매, 용해화제 또는 유탁화제 등이 사용될 수 있다. 예를 들어 상기 담체 성분으로 물, 알코올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르 등이 사용될 수 있다. 상기 알코올은 알코올 중 1종 이상을 의미하며, 바람직하게는 선형 또는 분지형의 C2-C4 모노알코올이며, 더욱 바람직하게는 에탄올 또는 이소프로판올을 사용할 수 있다. 특히 에탄올 또는 이소프로판올을 담체성분으로 사용하게되면 탈모 방지 또는 모발 성장 촉진용 조성물의 경피 흡수를 촉진할 수 있다.In one embodiment, when the formulation of the present invention is liquid, a solvent, a solubilizer or an emulsifier may be used as the carrier component. For example, water, alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan may be used as the carrier component. The alcohol refers to at least one type of alcohol, preferably a linear or branched C 2 -C 4 monoalcohol, and more preferably ethanol or isopropanol can be used. In particular, when ethanol or isopropanol is used as the carrier component, percutaneous absorption of the composition for preventing hair loss or promoting hair growth can be promoted.
일 실시예에서, 본 발명의 제형이 페이스트, 크림 또는 젤인 경우에는 담체 성분으로서 알코올, 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 사용될 수 있으며, 바람직하게는 알코올이 사용될 수 있고, 더욱 바람직하게는 상기 알코올은 이소프로판올일 수 있다.In one embodiment, when the formulation of the present invention is a paste, cream or gel, alcohol, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component, preferably alcohol may be used, and more preferably, the alcohol may be isopropanol.
일 실시예에서, 본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더 등이 이용될 수 있다. 특히 스프레이 제형인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르 등과 같은 추진체를 포함할 수 있다.In one embodiment, when the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component. In particular, when the formulation is a spray formulation, a propellant such as chlorofluorohydrocarbon, propane/butane, or dimethyl ether may be additionally included.
일 실시예에서, 본 발명의 조성물은 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상 외에 피부에 적용시킬 수 있는 외용제에 통상적으로 이용되는 성분들을 포함할 수 있다. 예를 들어 물, 계면활성제, 보습제, 저급알코올, 킬레이트제, 살균제, 산화방지제, 방부제, 색소 및 향료 등으로 이루어지는 군으로부터 선택되는 하나 이상의 첨가제가 추가로 포함될 수 있다.In one embodiment, the composition of the present invention may include, in addition to cordycepin; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate, ingredients commonly used in external preparations that can be applied to the skin. For example, one or more additives selected from the group consisting of water, surfactants, moisturizers, lower alcohols, chelating agents, bactericides, antioxidants, preservatives, colorants, and fragrances may be additionally included.
또한 본 발명은 상기 탈모 방지 또는 모발 성장 촉진용 조성물을 포함하는 헤어 또는 두피용 제품을 제공한다. 상기 헤어 또는 두피용 제품은 발모제, 두피클리닉제, 두피스케일링제, 두피마사지제, 두피케어제, 세정제, 샴푸, 토닉, 헤어컨디셔너, 헤어로션, 젤, 팩, 크림, 에센스, 파우더, 스프레이, 오일, 비누, 연고, 헤어스타일링제, 염모제 및 펌제 등으로 이루어진 군으로부터 선택된 어느 하나일 수 있으나, 이에 한정되지 않는다.In addition, the present invention provides a hair or scalp product comprising the composition for preventing hair loss or promoting hair growth. The hair or scalp product may be any one selected from the group consisting of hair tonics, scalp clinic agents, scalp scaling agents, scalp massage agents, scalp care agents, cleansers, shampoos, tonics, hair conditioners, hair lotions, gels, packs, creams, essences, powders, sprays, oils, soaps, ointments, hair styling agents, hair dyes, and perm agents, but is not limited thereto.
일 실시예에서, 본 발명의 탈모 방지 또는 모발 성장 촉진용 조성물은 헤어토닉 또는 헤어로션의 제형으로 제조될 수 있다. 본 발명의 모발 성장 촉진용 조성물은 바람직하게 피부에 직접 도포하거나 살포하는 등의 경피 투여 방법으로 사용될 수 있다. In one embodiment, the hair loss prevention or hair growth promotion composition of the present invention can be prepared in the form of a hair tonic or hair lotion. The hair growth promotion composition of the present invention can preferably be used by a transdermal administration method such as direct application to the skin or spraying.
또한 본 발명은 상기 탈모 방지 또는 모발 성장 촉진용 조성물을 포함하는 건강기능식품 조성물을 제공한다. 상기 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 건강기능식품은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 탈모 방지 및 발모 촉진 효과를 증진시키기 위한 보조제로 섭취가 가능하다.In addition, the present invention provides a health functional food composition including the composition for preventing hair loss or promoting hair growth. The health functional food can be manufactured by a method commonly used in the art, and can be manufactured by adding raw materials and ingredients commonly added in the art during the manufacturing process. In addition, the formulation of the health functional food can be manufactured without limitation as long as it is a formulation recognized as a health functional food. The health functional food of the present invention can be manufactured in various forms of formulations, and unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time since it uses food as a raw material, and has excellent portability, so the health functional food of the present invention can be taken as a supplement to enhance the effects of preventing hair loss and promoting hair growth.
또한, 본 발명은 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 유효성분으로 포함하는 탈모 방지 또는 모발 성장 촉진용 조성물을 환자에 투여하는 단계를 포함하는 탈모 방지 또는 모발 성장 촉진 방법을 제공한다.In addition, the present invention provides a method for preventing hair loss or promoting hair growth, comprising the step of administering to a patient a composition for preventing hair loss or promoting hair growth, which comprises as an effective ingredient at least one selected from the group consisting of cordycepin; and escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate.
본 발명에서 사용되는 용어, "투여"는 어떠한 적절한 방법으로 본 발명의 조성물을 도입하는 것을 의미할 수 있다. 본 발명의 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. 본 발명의 조성물은 경피 또는 경구 투여가 가능하며, 바람직하게는 경피 투여할 수 있으며, 그 중에서도 국소 도포가 가장 바람직하다. 본 발명의 조성물의 적용 횟수는 처방, 필요 또는 원하는 바에 따라 결정될 수 있다.The term "administration" used in the present invention may mean introducing the composition of the present invention by any suitable method. The route of administration of the composition of the present invention may be administered by any general route as long as it can reach the target tissue. The composition of the present invention may be administered transdermally or orally, preferably transdermally, and among them, topical application is most preferred. The number of times the composition of the present invention is applied may be determined according to the prescription, need, or desire.
본 발명에 기재된 모든 성분은, 바람직하게는, 한국, 중국, 미국, 유럽, 일본 등의 관련 법규, 규범 (예를 들어, 화장품 안전 기준 등에 관한 규정(한국), 화장품 안전 기술 규범(중국), 식품공전(한국), 식품첨가물공전(한국), 건강기능식품공전(한국)) 등에서 규정한 최대 사용치를 초과하지 않는다. 즉, 바람직하게, 본 발명에 따른 화장료, 식품, 또는 퍼스널 케어용 조성물은 각국의 관련 법규, 규범에서 허용되는 함량 한도로 본 발명에 따른 성분들을 포함한다.All of the ingredients described in the present invention preferably do not exceed the maximum usage levels specified in relevant laws and regulations of Korea, China, the United States, Europe, Japan, etc. (for example, Regulations on Cosmetic Safety Standards (Korea), Cosmetic Safety Technical Standards (China), Food Code (Korea), Food Additives Code (Korea), Health Functional Food Code (Korea)). That is, preferably, the cosmetic, food, or personal care composition according to the present invention contains the ingredients according to the present invention in the content limits permitted by relevant laws and regulations of each country.
본 발명은 인비트로 실험을 통해 본 발명의 조성물에 포함되는 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상이 모유두 세포의 활성을 증진시키고 Wnt/베타-카테닌 신호 전달 증폭을 통해 모발의 생리 주기를 퇴행기 내지 휴지기에서 활성기로 가는데 중요한 역할을 담당하는 것을 확인하였다(실험예 1 및 2).The present invention confirmed through in vitro experiments that cordycepin included in the composition of the present invention; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate enhances the activity of hair papilla cells and plays an important role in changing the hair menstrual cycle from the catagen or resting phase to the active phase through amplification of Wnt/beta-catenin signal transduction (Experimental Examples 1 and 2).
본 발명의 조성물의 사용량은 연령, 병변의 정도 등의 개인 차이나 제형에 따라 적절하게 조절될 수 있으며, 통상 1일 1회 내지 수회 적당량을 두피에 도포시켜 1주일 내지 수개월 사용하는 것이 바람직하다. 본 발명의 실험예에서는 탈모 치료 또는 모발 성장 촉진용 조성물을 1주에 5회씩 6개월 동안 사용하였으며, 그 결과 우수한 모발 성장 촉진 효과가 나타났음을 확인하였다(실험예 4).The amount of the composition of the present invention may be appropriately adjusted depending on individual differences such as age, degree of lesion, etc., and the formulation. It is usually preferable to apply an appropriate amount to the scalp once or several times a day and use it for one week to several months. In an experimental example of the present invention, a composition for hair loss treatment or hair growth promotion was used five times a week for six months, and as a result, it was confirmed that an excellent hair growth promotion effect was observed (Experimental Example 4).
본 발명의 탈모 방지 및/또는 모발 성장 촉진용 조성물은 모발 성장 효과가 우수하며 탈모 방지 또는 지연 효과도 우수하다.The composition for preventing hair loss and/or promoting hair growth of the present invention has an excellent hair growth effect and also an excellent hair loss prevention or delay effect.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 본 발명이 속한 분야에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, in order to help understand the present invention, examples and the like will be described in detail. However, the examples according to the present invention may be modified in various different forms, and the scope of the present invention should not be construed as being limited to the following examples. The examples of the present invention are provided to more completely explain the present invention to a person having average knowledge in the field to which the present invention belongs.
제조예 1: 탈모 치료 및/또는 발모 촉진용 조성물(헤어토닉)Manufacturing Example 1: Composition for treating hair loss and/or promoting hair growth (hair tonic)
하기 표 1에 개시된 처방에 따라 통상의 방법으로 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 유효성분으로 포함하는 헤어토닉 조성물을 실시예 1 내지 실시예 12로 제조하였다. 본 발명의 실험에 사용된 물질 및 시약들은 화장품 원료 제조사 및 상업용 공급 업체에서 구입하여 사용하였다. According to the prescription disclosed in Table 1 below, a hair tonic composition comprising cordycepin as an active ingredient; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate was prepared in Examples 1 to 12. The materials and reagents used in the experiments of the present invention were purchased from a cosmetic raw material manufacturer and a commercial supplier.
(총 100)Remaining amount
(Total 100)
제조예 2: 탈모 치료 및/또는 발모 촉진용 조성물(헤어로션)Manufacturing Example 2: Composition for treating hair loss and/or promoting hair growth (hair lotion)
하기 표 2에 개시된 처방에 따라 통상의 방법으로 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 유효성분으로 포함하는 헤어로션 조성물을 제조하였다. 본 발명의 실험에 사용된 물질 및 시약들은 화장품 원료 제조사 및 상업용 공급 업체에서 구입하여 사용하였다.According to the prescription disclosed in Table 2 below, a hair lotion composition containing cordycepin as an active ingredient and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate was prepared in a conventional manner. The materials and reagents used in the experiments of the present invention were purchased and used from cosmetic raw material manufacturers and commercial suppliers.
실험예 1: 모유두 세포 활성 증진 효과Experimental Example 1: Effect of promoting the activity of mammary papilla cells
인간 유래 모유두 세포(dermal papilla cells, DPCs)는 프로모셀사에서 구입하였다. 상기 DPCs을 5% 우태아 혈청(FBS; Gibco, NY, USA), 페니실린 100 unit/mL 및 스트렙토마이신 100 ㎍/mL이 포함된 DMEM (Hyclone Inc, UT, USA)에서 37℃ 및 5% CO2 조건하에 배양하였다. 배양한 DPCs 3,000 cells/well을 96-well 플레이트에 분주한 뒤, 0.1% 혈청 조건에서 24시간 동안 배양하였다. 그 후, 배양한 세포에 무혈청 DMEM에 1:1000으로 희석한 DMSO(vehicle)을 음성대조군으로, 미녹시딜 2 ㎍/㎖을 양성대조군으로 처리하였다. 또한, 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 각각 1일 동안 처리하고 인큐베이션 하였다. 인큐베이션 후 CCK방법을 이용하여 세포의 활성 증진 정도를 평가하였다. CCK-8을 배양액에 1:10으로 처리하여 1시간동안 인큐베이션 하였다. 1시간 후, 각 well의 흡광도 (absorbance)를 450nm으로 측정하였다. 모든 실험들은 3번씩 반복되었으며 흡광도 값의 평균을 계산하였다. 상기 결과들은 대조군을 100으로 하고 그에 비한 처리군의 퍼센트로 표현되었다.Human dermal papilla cells (DPCs) were purchased from Promocell. The DPCs were cultured in DMEM (Hyclone Inc, UT, USA) containing 5% fetal bovine serum (FBS; Gibco, NY, USA), 100 units/mL of penicillin, and 100 μg/mL of streptomycin at 37°C and 5% CO 2 . The cultured DPCs (3,000 cells/well) were dispensed into a 96-well plate and cultured for 24 hours under 0.1% serum conditions. Thereafter, the cultured cells were treated with DMSO (vehicle) diluted 1:1000 in serum-free DMEM as a negative control group and with 2 μg/mL of minoxidil as a positive control group. In addition, cordycepin; And at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate were treated and incubated for 1 day. After incubation, the degree of cell activity enhancement was evaluated using the CCK method. CCK-8 was treated in a ratio of 1:10 to the culture medium and incubated for 1 hour. After 1 hour, the absorbance of each well was measured at 450 nm. All experiments were repeated three times, and the average of the absorbance values was calculated. The results were expressed as the percentage of the treatment group compared to the control group, which was 100.
그 결과, 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 처리하였을 경우 우수한 모유두 세포(DPC) 활성 증진 효과를 나타내었다(표 3). 특히 코르디세핀을 포함하여 2종의 유효성분이 혼합된 실시예 25 내지 35는 단일 유효성분이 포함된 실시예 13 내지 24에 비해 모유두 세포 활성 증진 효과가 현저하게 우수하여, 2종의 유효성분의 조합을 통해 상승 효과가 발생함을 확인하였다.As a result, when cordycepin; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate was treated, an excellent effect of promoting dermal papilla cell (DPC) activity was exhibited (Table 3). In particular, Examples 25 to 35, in which two effective ingredients including cordycepin were mixed, showed a significantly superior effect of promoting dermal papilla cell activity compared to Examples 13 to 24, which contained a single effective ingredient, confirming that a synergistic effect occurred through the combination of two effective ingredients.
실험예 2: 모유두 세포 활성 신호(Wnt/베타-카테닌) 조절 효과Experimental Example 2: Effect of regulating the activation signal of mammary papilla cells (Wnt/beta-catenin)
일반적으로 모유두에서 활성화되는 Wnt/베타-카테닌 신호는 모발의 성장주기 중 퇴행기에서 활성기로 넘어올 때, 즉 모발이 자라기 시작할 때부터 모발 생장이 일어나는 활성기 동안에 걸쳐 일어난다. 또 휴지기 및 퇴행기에는 Wnt/베타-카테닌 신호가 약해지거나 없어지게 되어, 모낭이 퇴화하며 모발이 빠지는 현상이 일어난다. 따라서 본 발명의 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상이 Wnt/베타-카테닌 신호의 증폭에 얼마나 기여하는지 실험하였다.In general, the Wnt/beta-catenin signal, which is activated in the hair papilla, occurs during the transition from the catagen phase to the active phase of the hair growth cycle, that is, from the time when hair starts to grow to the active phase when hair growth occurs. In addition, the Wnt/beta-catenin signal is weakened or disappears during the telogen and catagen phases, causing hair follicles to degenerate and hair loss. Therefore, the extent to which cordycepin of the present invention; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate contributes to the amplification of the Wnt/beta-catenin signal was tested.
Wnt/베타-카테닌 신호를 증폭시키는 양성대조군으로는 wnt3a 단백질을 이용하였으며, 음성대조군으로는 DMSO를 사용하였다. 배양 96-well 플레이트에 Wnt 리포터 HEK293A 세포 3x104를 각 well에 시딩(seeding) 후, 본 발명의 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 각각 처리하고, Promega사의 루시퍼라제 분석 키트(Luciferase assay kit)(E1960)를 이용하여 리포터 분석을 진행하였다. 제조사의 실험방법을 따라서 진행하였고, luminometer Victor(PerkinElmer, Waltham, Massachusetts, USA)를 이용하여 Wnt/베타-카테닌 프로모터의 활성도를 측정하였다(표 4).As a positive control to amplify the Wnt/beta-catenin signal, wnt3a protein was used, and as a negative control, DMSO was used. 3x10 4 Wnt reporter HEK293A cells were seeded in each well of a 96-well culture plate, and then treated with at least one selected from the group consisting of cordycepin of the present invention; and escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate, and a reporter assay was performed using a luciferase assay kit (E1960) from Promega. The assay was performed according to the manufacturer's experimental method, and the activity of the Wnt/beta-catenin promoter was measured using a luminometer Victor (PerkinElmer, Waltham, Massachusetts, USA) (Table 4).
실험 결과를 볼 때, 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 처리하였을 경우 우수한 Wnt 신호 활성화 효과를 나타냄을 확인하였다. 특히 코르디세핀을 포함하여 2종의 유효성분이 혼합된 실시예 25 내지 35는 단일 유효성분이 포함된 실시예 13 내지 24에 비해 Wnt 신호 활성화 효과가 현저하게 우수하여, 2종의 유효성분의 조합을 통해 상승 효과가 발생함을 확인하였다.따라서, 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상은 모낭 줄기 세포의 모발 성장 촉진 신호인 Wnt/베타-카테닌 신호전달계의 활성을 매우 우수하게 촉진시킴으로써 발모 촉진의 효과가 있음을 확인할 수 있었다.As a result of the experiment, it was confirmed that when cordycepin; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate were treated, an excellent Wnt signal activation effect was exhibited. In particular, Examples 25 to 35, in which two types of effective ingredients including cordycepin were mixed, showed a significantly superior Wnt signal activation effect compared to Examples 13 to 24, which contained a single effective ingredient, confirming that a synergistic effect occurred through the combination of two types of effective ingredients. Therefore, cordycepin; And it was confirmed that at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate has an effect of promoting hair growth by very excellently promoting the activity of the Wnt/beta-catenin signaling system, which is a hair growth promoting signal of hair follicle stem cells.
실험예 3: 모발 체외 조직 배양(Ex-vivo)시 모발 성장 효과 확인Experimental Example 3: Confirmation of hair growth effect in ex vivo hair tissue culture
헬싱키 선언에 따라 병원에서 환자의 수술 등으로 제공받은 모발 조직 시료를 활용하여 체외 조직 배양(Ex-vivo)을 실시하였다. 실험 방법은 조직을 모발의 형태에 맞추어 잘라낸 후, William's E medium에 10μg/mL insulin, 10ng/mL hydrocortisone, 20mM HEPES, 및 1x antibiotic-antimycotic를 첨가한 배지에서 배양하였다. 본 발명의 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 각각 처리 후, 9일차에 모발 성장률을 측정하였다. In accordance with the Declaration of Helsinki, ex vivo tissue culture was performed using hair tissue samples provided by patients at hospitals through surgery, etc. The experimental method was to cut the tissue to the shape of the hair and then culture it in a medium containing 10 μg/mL insulin, 10 ng/mL hydrocortisone, 20 mM HEPES, and 1x antibiotic-antimycotic added to William's E medium. After treating with at least one selected from the group consisting of cordycepin of the present invention; and escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate, the hair growth rate was measured on the 9th day.
상기 실험 결과를 볼 때, 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 함유하는 실시예 13 내지 35에서 높은 모발 성장 효과가 나타남을 확인하였다. 특히 코르디세핀을 포함하여 2종의 유효성분이 혼합된 실시예 25 내지 35는 단일 유효성분이 포함된 실시예 13 내지 24에 비해 모발 성장 효과가 현저하게 우수하여, 2종의 유효성분의 조합을 통해 상승 효과가 발생함을 확인하였다.이를 통해, 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 유효성분으로 포함하는 본 발명의 탈모 방지 및/또는 모발 성장 촉진용 조성물이 탈모 치료에 매우 효과적으로 사용될 수 있음을 확인하였다.In view of the above experimental results, it was confirmed that Examples 13 to 35 containing cordycepin; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate exhibited a high hair growth effect. In particular, Examples 25 to 35, in which two types of effective ingredients including cordycepin were mixed, showed a significantly superior hair growth effect compared to Examples 13 to 24, which contained a single effective ingredient, confirming that a synergistic effect occurred through the combination of two types of effective ingredients. Through this, it was confirmed that cordycepin; And it was confirmed that the composition for preventing hair loss and/or promoting hair growth of the present invention, which comprises as an effective ingredient at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate, can be very effectively used for treating hair loss.
실험예 4: 탈모 치료 및/또는 발모 촉진용 조성물 1(헤어토닉)의 발모 효과 확인Experimental Example 4: Confirmation of hair growth effect of composition 1 (hair tonic) for hair loss treatment and/or hair growth promotion
모발의 수가 정상에 비해 현저히 적거나 탈모 증상이 있는 모발이 약한 남녀 총 210명을 대상으로 본 발명의 탈모 치료 및/또는 발모용 조성물 1(헤어토닉)의 발모 효과를 실험하였다. 상기 남녀 총 210명을 15명씩 14개 그룹으로 나누어 비교예 1, 2 및 실시예 1 내지 12를 사용하였으며, 1주에 5회씩 6개월 동안 모발 및 두피에 사용하였다. 사용 후 임상 사진 촬영을 통한 연구자 평가와 포토트리코그램을 통한 평가를 진행하였다. 임상 사진을 통한 연구자 평가는 도포 3, 6개월 뒤 비교예와 실험예에 대해 ‘good’, ‘slight’ ‘no change’ 3개 항목에 대해 평가를 진행하였다(good: 50%~75% 호전됨, slight: 25%~50% 호전됨, no change: 무변화). 비교예 및 실시예들을 도포하고 6개월 후에 포토트리코그램을 통한 단위면적당 모발 개수 및 평균 모발의 두께를 평가하였으며, 측정 결과를 표 6에 나타내었다.The hair growth effect of the hair loss treatment and/or hair growth composition 1 (hair tonic) of the present invention was tested on 210 men and women who had significantly less hair than normal or had weak hair with hair loss symptoms. The 210 men and women were divided into 14 groups of 15 each, and Comparative Examples 1 and 2 and Examples 1 to 12 were used on the hair and scalp 5 times a week for 6 months. After use, the researchers evaluated the results through clinical photographs and evaluated the results through phototrichogram. The researchers evaluated the results through clinical photographs for 3 and 6 months after application for the comparative examples and experimental examples, with three categories: ‘good’, ‘slight’ and ‘no change’ (good: 50% to 75% improvement, slight: 25% to 50% improvement, no change: no change). The comparative examples and examples were applied, and the number of hairs per unit area and the average hair thickness were evaluated six months later using a phototrichogram, and the measurement results are shown in Table 6.
상기 실험 결과를 볼 때, 상기 실험 결과를 볼 때, 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 함유하는 실시예 1 내지 12에서 탈모 방지 및 모발 성장 효과가 우수하게 나타남을 확인하였다. 이를 통해, 코르디세핀; 및 에스신, 아데노신, 알란토인, 병풀 추출물, 덱스판테놀, 나이아신아마이드, 살리실산, 퀘르시트린, 클로로젠산, 레인, 및 리보플라빈 5'-포스페이트로 이루어진 군으로부터 선택된 1종 이상을 유효성분으로 포함하는 본 발명의 탈모 방지 또는 모발 성장 촉진용 조성물이 탈모 치료에 매우 효과적으로 사용될 수 있음을 입증하였다. 상기 헤어토닉 또는 헤어로션과 같은 제형 예는 본 발명 탈모 방지 또는 모발 성장 촉진용 조성물의 예시일 뿐, 본 발명의 조성물의 범위가 이들 제형만으로 한정되지 않는다는 것은 당업계에서 통상의 지식을 가진자에게 자명할 것이다.In view of the above experimental results, it was confirmed that examples 1 to 12 containing cordycepin; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate exhibited excellent hair loss prevention and hair growth effects. Through this, it was proven that the hair loss prevention or hair growth promotion composition of the present invention containing cordycepin; and at least one selected from the group consisting of escin, adenosine, allantoin, centella asiatica extract, dexpanthenol, niacinamide, salicylic acid, quercitrin, chlorogenic acid, rhein, and riboflavin 5'-phosphate as effective ingredients can be very effectively used for hair loss treatment. The above-mentioned examples of formulations such as hair tonic or hair lotion are only examples of the composition for preventing hair loss or promoting hair growth of the present invention, and it will be apparent to those skilled in the art that the scope of the composition of the present invention is not limited to these formulations.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200113897A KR102708620B1 (en) | 2020-09-07 | 2020-09-07 | Composition for preventing hair loss and promoting hair growth |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200113897A KR102708620B1 (en) | 2020-09-07 | 2020-09-07 | Composition for preventing hair loss and promoting hair growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220033071A KR20220033071A (en) | 2022-03-16 |
| KR102708620B1 true KR102708620B1 (en) | 2024-09-20 |
Family
ID=80937634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200113897A Active KR102708620B1 (en) | 2020-09-07 | 2020-09-07 | Composition for preventing hair loss and promoting hair growth |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102708620B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102675965B1 (en) * | 2024-01-15 | 2024-06-14 | 주식회사 엘지생활건강 | Composition for improving skin blood circulation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103638038A (en) * | 2013-11-13 | 2014-03-19 | 青海互丰农业科技集团有限公司 | Chinese caterpillar fungus recuperation oral liquid used for treating alopecia, and formulas thereof |
| KR101509608B1 (en) * | 2014-12-29 | 2015-04-07 | 비오엠코스메틱 주식회사 | Composition for improving scalp and hair condition |
-
2020
- 2020-09-07 KR KR1020200113897A patent/KR102708620B1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103638038A (en) * | 2013-11-13 | 2014-03-19 | 青海互丰农业科技集团有限公司 | Chinese caterpillar fungus recuperation oral liquid used for treating alopecia, and formulas thereof |
| KR101509608B1 (en) * | 2014-12-29 | 2015-04-07 | 비오엠코스메틱 주식회사 | Composition for improving scalp and hair condition |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220033071A (en) | 2022-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101772574B1 (en) | A cosmetic composition for hair care comprising growth factors, highly stable basic fibroblast growth factor and noggin peptide to promote regeneration and growth of hair follicular cell | |
| KR102719515B1 (en) | Composition for Preventing Hair Loss or Promoting Hair Growth | |
| JP2024069595A (en) | Composition for preventing hair loss or promoting hair growth | |
| KR102675966B1 (en) | Composition for preventing hair loss and promoting hair growth | |
| KR20220126354A (en) | Hair cosmetic composition for preventing hair loss | |
| KR102063697B1 (en) | Composition for promoting the hair growth comprising escin | |
| JP7135106B2 (en) | Scalp and hair composition | |
| KR102708620B1 (en) | Composition for preventing hair loss and promoting hair growth | |
| CN112220794B (en) | Application of limonin in preventing alopecia and promoting hair growth | |
| US20230330120A1 (en) | Composition for preventing hair loss or promoting hair regrowth | |
| KR102537521B1 (en) | Composition for preventing hair loss and promoting hair growth | |
| KR102023021B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid | |
| JP7688038B2 (en) | Composition for preventing hair loss and promoting hair growth | |
| KR102074314B1 (en) | Composition for Preventing Hair Loss or Promoting Hair Growth | |
| KR102386651B1 (en) | Composition for preventing or treating hair loss comprising tiplaxtinin | |
| CN114929238B (en) | Composition for preventing alopecia and promoting hair growth | |
| KR20210082071A (en) | Composition for preventing hair loss and promoting hair growth | |
| KR20220162555A (en) | Composition for preventing hair loss and promoting hair growth comprising Gypsophila paniculata | |
| KR20090059230A (en) | Cosmetic composition to prevent hair loss, anti-inflammatory, hair root cell activation and hair growth | |
| CN117503748A (en) | Hair growth and hair loss prevention application of ethyl p-methoxycinnamate | |
| HK40021360A (en) | Composition for preventing hair loss or promoting hair growth | |
| KR20210023268A (en) | External composition for inhibiting hair loss and/or promoting hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20200907 |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211118 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20200907 Comment text: Patent Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230905 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240621 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240913 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240913 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |